
Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.
Paris - Topical imiquimod offers safe and often effective treatment for basal cell carcinomas (BCCs) in immunosuppressed, solid organ transplantation patients, David Vidal, M.D., said at the World Congress of Dermatology.






